Experimental cancer drug TNG908 tested in patients with MTAP gene deletion
NCT ID NCT05275478
First seen Nov 15, 2025 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This study tested an experimental drug called TNG908 in people with advanced solid tumors that lack the MTAP gene. The drug works by blocking a protein called PRMT5, which these cancer cells need to grow. The trial aimed to find a safe dose and see if the drug could shrink tumors, but it was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Carle Cancer Center
Urbana, Illinois, 61801, United States
-
Centre Léon Bérard
Lyon, 69373, France
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
EDOG Institut de Cancerologie de l'Ouest
Saint-Herblain, 44805, France
-
Florida Cancer Specialists & Research Institute
Lake Mary, Florida, 32746, United States
-
Grand Valley Oncology
Grand Junction, Colorado, 81505, United States
-
Institut Bergonié
Bordeaux, 33000, France
-
Institut Oncopole Claudius Regaud
Toulouse, 31059, France
-
Institute Gustav Roussy
Villejuif, 94805, France
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10022, United States
-
NEXT Oncology
Fairfax, Virginia, 22031, United States
-
NYU Langone Health
New York, New York, 10016, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, 80218, United States
-
Sarah Cannon Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of California San Francisco
San Francisco, California, 94143, United States
-
Washington University
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TNG908 (a PRMT5 inhibitor taken orally)
What this could lead to
If successful, this could point toward a new treatment option for certain hard-to-treat cancers that lack the MTAP gene.
What could go wrong
The trial was terminated early, so results are limited. It was an early-phase study, so even if safe, effectiveness is not guaranteed.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.